A newly proposed model suggests cancer cells may resist treatment not just through genetic mutations, but by dynamically reprogramming their gene activity. Credit: Shutterstock Cancer cells may “learn ...

Estimating that ReNU2 syndrome could account for around 10 percent of recessive neurodevelopmental disorder cases with a ...

In this interview, Dr. Michelle Fraser highlights how base editing and AI-designed enzymes are expanding therapeutic ...

Proteomics is emerging as a promising approach for identifying autism biomarkers by detecting protein-level changes linked to ...

AI is transforming medicine by improving diagnostics, personalized treatments, and operational efficiency. Key opportunities ...

Explore the recent advances in fuzzing, including the challenges and opportunities it presents for high-integrity software ...

We need investment in precision medicine technologies to start programming cancer against itself, writes Cyriac Roeding.

Genomic profiling enables therapy individualization when actionable mutations (FLT3, NPM1, IDH1/2, TP53) are present, moving ...

AI algorithms that can identify which patients are most likely to benefit from a drug recently backed for NHS use as a colorectal cancer (CRC) therapy have been developed by scien ...

A long-standing mystery in cancer treatment is how tumor cells so often become resistant to drugs, even ones they have never encountered before.

The idea that modern humans inherited DNA from Neanderthal ancestors is one of the 21st century’s most celebrated discoveries ...